tradmap

EHC Financials Encompass Health Corp

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Growth & profitability

  • Revenue has grown 10.7% per year over the past 5 years.
  • Net income has grown faster than revenue (14.8% vs 10.7% per year).
  • Free cash flow has grown 26.8% per year over the past 5 years.

Shareholder returns

  • Dividends have been paid for 13 consecutive years, consuming 12.6% of earnings and 16.2% of free cash flow.
  • The dividend has declined 8.7% per year over the past 5 years.
Revenue & net income
$0 $3B $6B 2011 2013 2015 2017 2019 2021 2023 2025
RevenueNet income
Margins (gross / operating / net)
0% 8% 16% 2011 2013 2015 2017 2019 2021 2023 2025
GrossOperatingNet
Return on equity & assets (ROE / ROA)
0% 89% 178% 2011 2013 2015 2017 2019 2021 2023 2025
ROEROA
Free cash flow (CFO − capex)
$0 $220M $439M 2011 2013 2015 2017 2019 2021 2023 2025
Free cash flow
Cash vs total debt
$0 $627M $1B 2011 2013 2015 2017 2019 2021 2023 2025
CashTotal debt
Cash flow: operating / investing / financing
-$1B $23M $1B $0 2011 2013 2015 2017 2019 2021 2023 2025
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MROEROAFCFTotal debtCash
2025 $5.9B $566M 0.0% 0.0% 23.2% 8.0% $439M — $72M
2024 $5.4B $456M 0.0% 0.0% 22.0% 7.0% $360M — $85M
2023 $4.8B $352M 0.0% 0.0% 21.4% 5.8% $268M — $69M
2022 $4.3B $271M 0.0% 12.4% 20.7% 4.8% $122M — $22M
2021 $4.0B $412M 0.0% 13.9% 21.6% 6.0% $170M — $49M
2020 $3.6B $284M 0.0% 15.8% 17.9% 4.4% — — $186M
2019 $4.6B $359M 0.0% 13.3% 26.5% 5.9% — — $60M
2018 $4.3B $292M 0.0% 13.0% 22.9% 5.6% — — $69M
2017 $3.9B $271M 0.0% 14.8% 23.5% 5.6% — — $54M
2016 $3.6B $248M 0.0% 16.1% 33.6% 5.3% — — $41M
2015 — $183M — — 29.9% 4.0% — — $62M
2014 — $222M — — 46.9% 6.6% — — $67M
2013 — $324M — — 93.9% 12.8% — — $65M
2012 — $185M — — 63.6% 7.6% — — $133M
2011 — $209M — — 178.4% 9.2% — $1.3B $30M

Valuation over time

How the market has priced EHC against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

Price / earnings (P/E)
0.0 14.4 28.9 Mar '23 Sep '23 Mar '24 Sep '24 Mar '25 Sep '25 Mar '26 Sep '26
P/E
Price / sales (P/S)
0.0 1.2 2.3 Mar '23 Sep '23 Mar '24 Sep '24 Mar '25 Sep '25 Mar '26 Sep '26
P/S
Dividend yield (%)
0.0 0.9 1.9 Mar '23 Sep '23 Mar '24 Sep '24 Mar '25 Sep '25 Mar '26 Sep '26
Dividend yield %

Frequently asked questions

Is EHC growing its revenue and profit?

Over the past 5 years, Encompass Health Corp's revenue has grown 10.7% per year, and net income grown 14.8% per year. These are computed facts, not advice.

How much debt does EHC have?

As of FY2025, Encompass Health Corp reported — of total debt against $72M of cash.

What is EHC's profit margin?

In FY2025, gross margin was —, operating margin —, and net margin 9.5%.

What is EHC's P/E ratio?

Encompass Health Corp's P/E (TTM) is 21.80 as of the 2026-11-02 close — market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year, the same figure as on the EHC stock page. The valuation chart above sets each month-end's price against the latest annual net income instead, so its latest point (about 23.9× as of Nov '26) can differ. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.